Friday, December 16, 2022 8:32:02 PM
The law of unintended consequences.
Most of you are overly invested in Acadia pharma.
Most of you are deep underwater with your investment.
Most of you have averaged down and even taken out a 2nd mortgage to do so.
Most of you are hoping that Trofinetide will be FDA approved for RETT syndrome on March 12th, 2023.
Most of you think Acadia's share price will rise upon FDA approval.
Most of you are just hoping to break even to bail out of this Titanic boat anchor.
Most of you don't realize that the stock price will dive upon Trofinetide approval.
It costs more to manufacture and sell Trofinetide, than full sales could ever pay for let alone make a profit.
The same is true of Nuplazid, it costs more to manufacture and sell, than any meager "profits" can bring in.
The Baker Brothers only own Acadia pharma stock, as a tax write-off...
Every hedge fund, needs one bad apple in the bunch, just to offset taxes on the other, profitable holdings.
Criss-Cross, you bet the wrong dog!
Recent ACAD News
- Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship • Business Wire • 04/29/2024 08:16:00 PM
- Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024 • Business Wire • 04/24/2024 08:05:00 PM
- Acadia Pharmaceuticals annonce que la présentation de drogue nouvelle pour la trofinetide dans le traitement du syndrome de Rett a été acceptée pour dépôt et évaluation prioritaire par Santé Canada • Business Wire • 04/22/2024 01:04:00 PM
- Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada • Business Wire • 04/22/2024 01:04:00 PM
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/19/2024 08:05:00 PM
- Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting • Business Wire • 04/17/2024 08:05:00 PM
- Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development • Business Wire • 04/02/2024 08:05:00 PM
- Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference • Business Wire • 04/01/2024 08:05:00 PM
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/15/2024 08:05:00 PM
- Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day • Business Wire • 03/13/2024 08:05:00 PM
- Oracle Soars 13% With Exceptional Growth and Boosts Nvidia Shares With Collaboration Announcement, and More • IH Market News • 03/12/2024 11:21:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:05:55 PM
- Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia • Business Wire • 03/11/2024 08:05:00 PM
- Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024 • Business Wire • 02/29/2024 02:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:13:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:10:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:07:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:02:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:16:24 PM
- Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview • Business Wire • 02/27/2024 09:05:00 PM
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 02/21/2024 09:05:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 12:08:13 PM
- Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 • Business Wire • 02/13/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/08/2024 10:09:17 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/08/2024 10:05:48 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM